KEY POINTS
  • The economic costs of China's zero-Covid policy is increasingly expected to outweigh its benefits, according to investment bank Morgan Stanley.
  • The bank has now cut its forecast for the first quarter GDP to 4.5%.
  • "At this point, we think investors are still being too bullish with their expectation about corporate earnings," said Laura Wang, chief China equity strategist at the firm.
A woman shows her swab and test kit to a health worker before receiving a nucleic acid test for Covid-19 at a private testing site on January 17, 2022 in Beijing, China.

The economic costs of China's zero-Covid policy are increasingly expected to outweigh its benefits, according to U.S. investment bank Morgan Stanley.

China's zero tolerance for Covid leaves the country at a disadvantage compared to other countries with an endemic strategy, its chief China equity strategist Laura Wang told CNBC's Emily Tan.